PharmaFocus Today – Page 2 – media

Got Pruney Fingers? Here’s The Scientific Skinny To Explain It

As swimming season heats up, you might notice your fingers wrinkle after spending time in the water — turns out, those wrinkles are the same with every dip you take. And that, researchers from Binghamton University, State University of New York, could have useful applications for crime investigators. Guy German and his team at SUNY’s Biological Soft Matter Mechanics Laboratory discovered that the wrinkles come from blood vessels contracting under the skin and not from skin swelling, as folks once thought. German had previously studied this in 2023, he explained, but a student’s follow-up question inspired more research. “A student asked, ‘Yeah, but do the wrinkles always form in the same way?’ And I thought: ‘I haven’t the foggiest clue!’ ” said German, who teaches biomedical engineering at the Thomas J. Watson College of Engineering and Applied Science. In a study published in the Journal of the Mechanical Behavior ...
- Source: drugdu
- 51
- May 20, 2025
Clinical Trials Have a Research Site Demand and Supply Crisis. Here is How to Solve it

Clinical research sites face an information challenge that hinders efficiency and collaboration. As trial complexity increases, the multiple logins, devices, and spreadsheets site staff use to execute studies create siloed workstreams. In addition, each sponsor has its preferred software solutions for every trial, making collecting, accessing, and sharing data a tedious effort. The outcome is overburdened investigators who are stretched too thin. The impact is significant on-site capacity and is likely why a recent survey report found that more than half of clinical sites struggle to take on new trials. A significant drop in physicians entering clinical research — from 5% to less than 2% annually — compounds the problem. Emphasizing the supply and demand imbalance, 29% of the sites that take on a trial fail to enroll patients. Realizing that fewer sites are participating in trials, the industry is beginning to come together and address the core needs ...
- Source: drugdu
- 43
- May 20, 2025
Aimi Vaccine mRNA shingles vaccine approved for clinical trials

On May 19, Aimi Vaccine (06660) announced that its mRNA shingles vaccine has recently obtained the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration, which corresponds to the approval of the U.S. Food and Drug Administration for clinical trials in March 2025. This dual approval fully verifies the strength of the company’s mRNA technology platform. In preclinical trials, results from third-party testing units showed that the vaccine developed by the company was significantly higher than the internationally marketed recombinant subunit control vaccine in terms of specific T cell immunity, specific IgG antibody titer and membrane antigen fluorescent antibody (FAMA) titer. Currently, no mRNA shingles vaccine has been approved for marketing internationally, and the market potential is huge. It is estimated that by 2030, the Chinese market size will reach about 20 billion yuan, and the global market size will reach about 23.9 billion US dollars. The launch ...
- Source: drugdu
- 38
- May 20, 2025
Customized gene therapy! The first clinical application of human patients is completed

An international research team recently published a paper in the New England Journal of Medicine, saying that they successfully implemented customized gene editing therapy for a baby with a rare genetic disease. The National Institutes of Health issued a statement on the same day saying that this is the first time that gene therapy has been customized clinically applied in human patients, laying the foundation for the development of customized gene therapy for other rare diseases in the future. The baby was diagnosed with carbamoyl phosphate synthetase 1 (CPS1) deficiency shortly after birth, a rare genetic disease characterized by the inability of the patient’s liver to completely break down certain substances produced during protein metabolism, causing ammonia to accumulate to toxic levels in the body, thereby impairing brain and liver function. The mortality rate of patients with this disease in early infancy is about 50%. Researchers from the United States, ...
- Source: drugdu
- 36
- May 20, 2025
InnoChip International received RMB 100 million in Series B financing to reconstruct the organoid technology ecosystem and lead the global bioindustry transformation

On May 19, 2025, Chuangxin International Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as “Chuangxin International”) officially announced the completion of nearly RMB 100 million in Series B financing. This round of financing was jointly led by Guangdong Science and Technology Fund and Zhongshan Hao Chuang Fund under Donghai Investment Control, helping Chuangxin International accelerate the research and development transformation of organoid technology and global commercial layout, injecting strong innovation momentum into the biomedical field. As a leading enterprise in the whole industry chain of organoids, Chuangxin International has built an integrated ecological platform covering the whole life cycle of organoids based on its core technology system of independent innovation. The company focuses on three strategic directions: precision medicine, new drug research and development, and intelligent manufacturing. It focuses on the large-scale application of organoid tumor treatment, regenerative medicine, and synthetic biology, breaks through the key bottlenecks of the industry, ...
- Source: drugdu
- 34
- May 20, 2025
Opportunity moment for Chinese ADC

Recently, Eli Lilly announced that its Nectin-4 targeted ADC drug LY4052031 has suspended clinical trials due to safety issues. Nectin-4 is a hot target for ADC drug development. Currently, only one Nectin-4 targeted ADC product has been approved for marketing in the world, namely Padcev, which is approved for the treatment of urothelial carcinoma. Eli Lilly has deployed two next-generation anti-nectin-4 ADC drugs: LY4052031 (the toxin is the DNA topoisomerase I inhibitor camp98) and LY4101174 (the toxin is exatecan). This suspension involves LY4052031, while LY4101174 is still in Phase I clinical trials, and its efficacy and toxicity in humans remain to be observed. This incident also aroused the industry’s attention to the safety of Nectin-4 ADC, and exposed the difficulties in the research and development of ADC drugs: payload toxicity control, linker stability, any “shortcomings” in any link may trigger a chain reaction. 1. China’s Biotech industry faces opportunities Nectin-4 ...
- Source: drugdu
- 35
- May 20, 2025
Mabwell Biopharma and Shenshi Technology have reached a strategic cooperation to build a large model platform for biopharmaceutical R&D

On May 14, Mabwell Biotech and Shenshi Technology jointly announced a strategic cooperation. Both parties will give full play to their respective strengths in biopharmaceutical research and development and artificial intelligence.(AI) big model advantages, jointly build a big model platform for biopharmaceutical R&D, and jointly build innovative drugs Develop a new paradigm. Mabwell Biopharma has outstanding advantages in the construction of ADC technology platforms and the discovery of single/double antibody molecules, and has opened up the entire industry chain of ADC drugs from research and development to production. The independently developed IDDC platform and Mtoxin toxin technology have been verified in many projects. Shenshi Technology has built a complete microscopic world cognition and computing system with its independently developed Uni-Smart scientific literature multimodal model, Uni-Mol molecular conformation model and Uni-Fold protein folding model and other series of life science models. The two parties will cooperate in two directions: First, knowledge ...
- Source: drugdu
- 42
- May 19, 2025
CanSino’s inhaled tuberculosis vaccine approved for clinical trials in Indonesia

May 15, CanSino(688185/06185) announced that the company’s inhaled tuberculosis vaccine (adenovirus type 5 vector) has recently obtained clinical trial approval from the Indonesian Food and Drug Administration. The development of this vaccine aims to solve the problem of BCG’s weakening protection over time and provide more effective immune protection. According to the World Health Organization, there will be 10.8 million new tuberculosis patients worldwide in 2023, showing the continued threat of tuberculosis, especially in Southeast Asia and Africa. This Phase I clinical trial will explore the safety and immunogenicity of the vaccine in adults aged 18-49. In the first quarter of 2025, CanSino Biologics achieved revenue of 137 million yuan and a net profit attributable to shareholders of the parent company of -11.55 million yuan. https://finance.eastmoney.com/a/202505153405639359.html
- Source: drugdu
- 42
- May 19, 2025
Xinghao Pharmaceutical’s Docetaxel Injection Receives FDA Approval of Abbreviated New Drug Application (ANDA)

On May 15, Xinghao Pharmaceutical announced that Guangdong Xinghao Pharmaceutical Co., Ltd. recently obtained approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for docetaxel injection. This approval qualifies the company to sell the drug in the U.S. market, marking an important step for the company in expanding overseas markets. Docetaxel injection is indicated for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer and head and neck cancer. The dosage form is injection with specifications of 80mg/4mL and 20mg/1mL. In the first quarter of 2025, Xinghao Pharmaceutical achieved revenue of 142 million yuan and net profit attributable to shareholders of the parent company of 25.03 million yuan. https://finance.eastmoney.com/a/202505153405776677.html
- Source: drugdu
- 39
- May 19, 2025
North China Pharmaceutical’s subsidiary’s recombinant tetanus vaccine approved for clinical trials

On May 15, North China Pharmaceutical(600812) announced that its subsidiary Jintan Company recently received the “Drug Clinical Trial Approval Notice” for the recombinant tetanus vaccine (Escherichia coli) approved and issued by the National Medical Products Administration. The acceptance number of the notice is CXSL2500168, the notice number is 2025LP01313, the dosage form is injection, the specification is 30μg/0.5ml/piece, and the approval conclusion shows that the vaccine meets the relevant requirements for drug registration and agrees to conduct clinical trials. As of April 2025, Jintan’s cumulative R&D expenses for this drug are RMB 39.71 million (unaudited). Currently, there is no recombinant tetanus vaccine based on genetic engineering on the market at home and abroad, and Jintan’s R&D will fill this market gap. In the first quarter of 2025, North China Pharmaceutical achieved revenue of 2.574 billion yuan and net profit attributable to shareholders of the parent company of 57.49 million yuan. ...
- Source: drugdu
- 41
- May 19, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.